

David DeWorsop

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3862333/publications.pdf>

Version: 2024-02-01

44
papers

2,554
citations

257450

24
h-index

265206

42
g-index

45
all docs

45
docs citations

45
times ranked

3226
citing authors

#	ARTICLE	IF	CITATIONS
1	Going deep into schizophrenia with artificial intelligence. <i>Schizophrenia Research</i> , 2022, 245, 122-140.	2.0	39
2	mTORC1 inhibitor effects on rapid ketamine-induced reductions in suicidal ideation in patients with treatment-resistant depression. <i>Journal of Affective Disorders</i> , 2022, 303, 91-97.	4.1	22
3	Timing of cannabis exposure relative to prodrome and psychosis onset in a community-based first episode psychosis sample. <i>Journal of Psychiatric Research</i> , 2022, 147, 248-253.	3.1	4
4	Editorial. <i>Psychopharmacology</i> , 2022, , 1.	3.1	0
5	Preliminary in vivo evidence of lower hippocampal synaptic density in cannabis use disorder. <i>Molecular Psychiatry</i> , 2021, 26, 3192-3200.	7.9	32
6	Psychosocial and pharmacological treatments for cannabis use disorder and mental health comorbidities: a narrative review. <i>Psychological Medicine</i> , 2021, 51, 353-364.	4.5	17
7	Exocannabinoids, Endocannabinoids, and Psychosis. <i>Biological Psychiatry: Cognitive Neuroscience and Neuroimaging</i> , 2021, 6, 600-602.	1.5	0
8	Differential Cognitive Performance in Females and Males with Regular Cannabis Use. <i>Journal of the International Neuropsychological Society</i> , 2021, 27, 570-580.	1.8	6
9	Identifying brain networks in synaptic density PET (11C-UCB-J) with independent component analysis. <i>NeuroImage</i> , 2021, 237, 118167.	4.2	18
10	Cannabis and Driving. <i>Frontiers in Psychiatry</i> , 2021, 12, 689444.	2.6	36
11	Assessment of transient dopamine responses to smoked cannabis. <i>Drug and Alcohol Dependence</i> , 2021, 227, 108920.	3.2	4
12	In vivo 5-HT6 and 5-HT2A receptor availability in antipsychotic treated schizophrenia patients vs. unmedicated healthy humans measured with [11C]GSK215083 PET. <i>Psychiatry Research - Neuroimaging</i> , 2020, 295, 111007.	1.8	17
13	Alterations in the Endocannabinoid System in Schizophrenia. <i>Biological Psychiatry</i> , 2020, 88, 675-677.	1.3	2
14	The state of clinical outcome assessments for cannabis use disorder clinical trials: A review and research agenda. <i>Drug and Alcohol Dependence</i> , 2020, 212, 107993.	3.2	49
15	Association of Ketamine With Psychiatric Symptoms and Implications for Its Therapeutic Use and for Understanding Schizophrenia. <i>JAMA Network Open</i> , 2020, 3, e204693.	5.9	103
16	Cannabis in psychiatric disorders: the cart before the horse?. <i>Lancet Psychiatry</i> , the, 2019, 6, 968-969.	7.4	2
17	Test-retest reliability of time-frequency measures of auditory steady-state responses in patients with schizophrenia and healthy controls. <i>NeuroImage: Clinical</i> , 2019, 23, 101878.	2.7	31
18	Efficacy and safety of a fatty acid amide hydrolase inhibitor (PF-04457845) in the treatment of cannabis withdrawal and dependence in men: a double-blind, placebo-controlled, parallel group, phase 2a single-site randomised controlled trial. <i>Lancet Psychiatry</i> , the, 2019, 6, 35-45.	7.4	125

#	ARTICLE	IF	CITATIONS
19	Medical Marijuana. <i>Journal of Clinical Psychiatry</i> , 2019, 80, .	2.2	5
20	Age-Related Change in 5-HT ₆ Receptor Availability in Healthy Male Volunteers Measured with ¹¹ C-GSK215083 PET. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1445-1450.	5.0	34
21	Dose-Related Target Occupancy and Effects on Circuitry, Behavior, and Neuroplasticity of the Glycine Transporter-1 Inhibitor PF-03463275 in Healthy and Schizophrenia Subjects. <i>Biological Psychiatry</i> , 2018, 84, 413-421.	1.3	43
22	Minimal effects of prolonged smoking abstinence or resumption on cognitive performance challenge the "self-medication" hypothesis in schizophrenia. <i>Schizophrenia Research</i> , 2018, 194, 62-69.	2.0	26
23	Tetrahydrocannabinol (THC) impairs encoding but not retrieval of verbal information. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2017, 79, 176-183.	4.8	27
24	Feasibility and success of cell-phone assisted remote observation of medication adherence (CAROMA) in clinical trials. <i>Drug and Alcohol Dependence</i> , 2016, 163, 24-30.	3.2	23
25	Reduced Brain Cannabinoid Receptor Availability in Schizophrenia. <i>Biological Psychiatry</i> , 2016, 79, 997-1005.	1.3	83
26	Rapid Changes in Cannabinoid 1 Receptor Availability in Cannabis-Dependent Male Subjects After Abstinence From Cannabis. <i>Biological Psychiatry: Cognitive Neuroscience and Neuroimaging</i> , 2016, 1, 60-67.	1.5	135
27	Human Laboratory Studies on Cannabinoids and Psychosis. <i>Biological Psychiatry</i> , 2016, 79, 526-538.	1.3	113
28	Marijuana and Madness: Associations Between Cannabinoids and Psychosis. <i>Biological Psychiatry</i> , 2016, 79, 511-513.	1.3	13
29	Marijuana Legalization: Impact on Physicians and Public Health. <i>Annual Review of Medicine</i> , 2016, 67, 453-466.	12.2	147
30	GABA Deficits Enhance the Psychotomimetic Effects of ⁹ -THC. <i>Neuropsychopharmacology</i> , 2015, 40, 2047-2056.	5.4	29
31	⁹ -THC Disrupts Gamma (̳)-Band Neural Oscillations in Humans. <i>Neuropsychopharmacology</i> , 2015, 40, 2124-2134.	5.4	57
32	Medical Marijuana. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 2431.	7.4	75
33	The Psychosis-like Effects of ⁹ -Tetrahydrocannabinol Are Associated With Increased Cortical Noise in Healthy Humans. <i>Biological Psychiatry</i> , 2015, 78, 805-813.	1.3	44
34	Effects of Nicotine on the Neurophysiological and Behavioral Effects of Ketamine in Humans. <i>Frontiers in Psychiatry</i> , 2014, 5, 3.	2.6	34
35	Gone to Pot? A Review of the Association between Cannabis and Psychosis. <i>Frontiers in Psychiatry</i> , 2014, 5, 54.	2.6	235
36	Problems With the Medicalization of Marijuana. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 2377.	7.4	40

#	ARTICLE	IF	CITATIONS
37	Medicalization of Marijuanaâ€™Reply. JAMA - Journal of the American Medical Association, 2014, 312, 1931.	7.4	1
38	Impact of Cannabis Use on the Development of Psychotic Disorders. Current Addiction Reports, 2014, 1, 115-128.	3.4	109
39	Pilot study of Intravenous Nicotine Effects on Cognitive Performance in Schizophrenia. Schizophrenia Research, 2013, 150, 323-324.	2.0	4
40	Glycine Transporter Inhibitor Attenuates the Psychotomimetic Effects of Ketamine in Healthy Males: Preliminary Evidence. Neuropsychopharmacology, 2012, 37, 1036-1046.	5.4	58
41	Lower $\hat{I}^2_{sub>2</sub>}$ *-Nicotinic Acetylcholine Receptor Availability in Smokers With Schizophrenia. American Journal of Psychiatry, 2012, 169, 326-334.	7.2	59
42	Cannabinoids and Psychosis. International Review of Neurobiology, 2007, 78, 289-326.	2.0	83
43	Delta-9-tetrahydrocannabinol effects in schizophrenia: Implications for cognition, psychosis, and addiction. Biological Psychiatry, 2005, 57, 594-608.	1.3	524
44	Glycine Site Agonists of the NMDA Receptor: A Review. CNS Neuroscience & Therapeutics, 1995, 1, 227-260.	4.0	46